November 2, 2022 · Posted in Uncategorized 
October 28, 2022
FEATURED NEWS: First and Only Oral NDMA Receptor Antagonist for MDD Can Now Be Prescribed
Extended-release dextromethorphan HBr-bupropion HCl (Auvelity™), the only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for the treatment of major depressive disorder (MDD), is now available by prescription in the United States, maker Axsome Therapeutics Inc. announced.  The drug is supplied in 105-mg tablets in 30-count bottles.On August 18th, 2022, the US Food and Drug Administration (FDA) approved dextromethorphan HBr-bupropion HCl extended-release tablets 45mg/105mg 

Comments

Comments are closed.